Enfusion, Inc. (NYSE:ENFN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN) have earned an average recommendation of “Reduce” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $9.40.

Separately, Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday.

Enfusion Price Performance

Shares of Enfusion stock remained flat at $11.03 during trading on Wednesday. 127,814 shares of the stock traded hands, compared to its average volume of 384,704. The stock’s 50-day simple moving average is $9.61 and its 200 day simple moving average is $8.97. The stock has a market cap of $1.42 billion, a P/E ratio of 275.82, a PEG ratio of 3.98 and a beta of 0.97. Enfusion has a 1-year low of $7.52 and a 1-year high of $11.38.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 36.44% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after purchasing an additional 70,367 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after acquiring an additional 61,032 shares during the last quarter. State Street Corp raised its stake in shares of Enfusion by 2.3% during the third quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after acquiring an additional 21,729 shares during the last quarter. Impax Asset Management Group plc raised its stake in shares of Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after acquiring an additional 136,948 shares during the last quarter. Finally, Scalar Gauge Management LLC raised its stake in shares of Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after acquiring an additional 110,000 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.